Digital Look

Welcome to Digital Look++,
you are not logged in

Thalia Therapeutics (THAT)

Pharma and Biotech

0.64p

2016-10-17 - Suspension of Listing

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-21	n/a	(1.84)	(0.85)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	n/a	(1.19)	(0.55)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	n/a	(1.42)	(0.52)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-24	0.01	(1.22)	(31.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-25	0.01	(1.16)	(17.00)¢	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

No recent information was found.

Thalia Therapeutics enters new phase of developm...	17-Jul-2026	ShareCast
N4 Pharma appoints new CEO, proposes name change	24-Feb-2026	ShareCast
N4 Pharma reports narrower full-year operating l...	06-Jun-2025	ShareCast

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.